Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI‐110) in Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There is an urgent need to develop more effective therapies for hepatocellular carcinoma (HCC) because of its aggressiveness. Guadecitabine (SGI‐110) is a second‐generation DNA methyltransferase inhibitor (DNMTi), which is currently in clinical trials for HCC and shows greater stability and performance over first‐generation DNMTis. In order to identify potential therapeutic targets of SGI‐110 for clinical trials, HCC cell lines (SNU398, HepG2, and SNU475) were used to evaluate the effects of transient SGI‐110 treatment by an integrative analysis of DNA methylation, nucleosome accessibility, gene expression profiles, and its clinical relevance by comparison to The Cancer Genome Atlas (TCGA) HCC clinical data. Each HCC cell line represents a different DNA methylation subtype of primary HCC tumors based on TCGA data. After SGI‐110 treatment, all cell lines were sensitive to SGI‐110 with prolonged antiproliferation effects. Expression of up‐regulated genes, including tumor suppressors, was positively correlated with nucleosome accessibility and negatively correlated with gene promoter DNA methylation. Alternatively, expression of down‐regulated genes, such as oncogenes, was negatively correlated with nucleosome accessibility and positively correlated with gene body DNA methylation. SGI‐110 can also act as a dual inhibitor to down‐regulate polycomb repressive complex 2 (PRC2) genes by demethylating their gene bodies, resulting in reactivation of PRC2 repressed genes without involvement of DNA methylation. Furthermore, it can up‐regulate endogenous retroviruses to reactivate immune pathways. Finally, about 48% of frequently altered genes in primary HCC tumors can be reversed by SGI‐110 treatment. Conclusion: Our integrative analysis has successfully linked the antitumor effects of SGI‐110 to detailed epigenetic alterations in HCC cells, identified potential therapeutic targets, and provided a rationale for combination treatments of SGI‐110 with immune checkpoint therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“(22,23) The traditional view on DNMTi treatment involves reactivation of tumor suppressor genes by DNA demethylation to suppress tumor growth and reverse the malignant phenotype.(24,25) However, the level of DNA demethylation does not always correlate with the level of gene reactivation and/or predict clinical outcome.”
BackgroundComprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationChiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022 · cited 7×
“Recent investigations including several from our group suggest that oncogene down-regulation through gene body DNA demethylation, activation of endogenous retroviral elements (ERVs), and an antiviral defense response contribute to the clinical efficacy of DNMTis.(26-28) Because DNA methylation has tissue-specific and…”
BackgroundMethodResultInfluentialSelf-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 3×
“(28) These genes are regulated by transcription factors such as NFY, E2F, and EVI1 and belong to pathways such as WNT, TGFβ, and phosphoinositide 3-kinase signaling, which were shown to be associated with HCC or other malignancies.(8,36-38,45) In addition, we find that high expression levels of the NFY family of genes…”
BackgroundGene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
Self-citationValidation of a DNA methylation microarray for 450,000 CpG sites in the human genome
Sandoval, J., Heyn, H., Moran, S., Serra-Musach, J., Pujana, M. A., Bibikova, M., & Esteller, M. (2011) · Epigenetics · doi:10.4161/epi.6.6.16196 · Cited by 990 · cited 1×
“(8) The HM450 platform contains probes for 482,421 CpG sites across the human genome, covering 99% of RefSeq genes (more than 21,000 genes); and the probes are distributed in promoters, gene bodies, enhancers, and intergenic regions.(34) Unsupervised clustering of the TCGA HCC DNA methylation data set identified three…”
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Guler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · cited 1×
“(26,27,39) Thus, we expect that SGI-110 may be even more efficacious in combination with other cancer treatment drugs at up-regulating ERVs or transposable elements and subsequently increasing sensitivity to immune checkpoint therapies(46) and resensitizing drug-resistant tumor cells.(47) Taken together, our findings…”
BackgroundVitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225
Self-citationGenome-wide DNA methylation profiles in hepatocellular carcinoma
Shen, J., Wang, S., Zhang, Y.-J., Kappil, M., Wu, H.-C., Kibriya, M. G., Wang, Q., Jasmine, F., Ahsan, H., Lee, P.-H., et al. (2012) · Hepatology · doi:10.1002/hep.25569 · Cited by 196 · cited 1×
“Indeed, DNA methylation alterations frequently occur in HCC and are integral to the initiation and progression of the disease.(6-8) US Food and Drug Administration (FDA)–approved DNMTis, such as 5′-aza-2′-deoxycytidine (5-aza-CdR or decitabine) and 5-azacytidine (5-aza-CR or Vidaza), were developed and represented the…”
Background
Cited by
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
Epigenetics in hepatocellular carcinoma
Nagaraju, G. P., Dariya, B., Kasa, P., Peela, S., & El-Rayes, B. F. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.07.017 · Cited by 339
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
“Moreover, SGI110 robustly reactivated the expression of epigenetically silenced endogenous retroviruses in HCC cells, triggering an innate immune response that can be harnessed to improve ICI sensitivity in vivo.(136,148) The results of clinical trials testing SGI110 administered alone or in combination with other ant…”
BackgroundNO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance
Xu, Q., Chen, G., Chen, G., Wu, H., Yang, Y., Mai, Z., Sun, R., Luan, P., Guo, C., Yu, M., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.022 · Cited by 35
Metadata
- Authors
- Liu, M., Zhang, L., Li, H., Hinoue, T., Zhou, W., Ohtani, H., El‐Khoueiry, A., Daniels, J., O'Connell, C., Dorff, T. B., Lu, Q., Weisenberger, D. J., & Liang, G.
- Venue
- Hepatology
- Published
- 2018-10
- Volume
- 68
- Issue
- 4
- Pages
- 1412-1428
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2803869134
- Cited by
- 65
- References
- 11
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.